Table 3.
Correlation between CD8 expression and clinicopathologic parameters in thymic carcinoma.
| Parameters | CD8 (N = 59) | ||
|---|---|---|---|
|
High
(n = 4, %) |
Low
(n = 55, %) |
P-value | |
| Age† | 52.8 ± 18.30 | 56.1 ± 10.79 | 0.037 |
| Gender | 0.647 | ||
| Male | 3 (75.0%) | 35 (63.6%) | |
| Female | 1 (25.0%) | 20 (36.4%) | |
| Masaoka stage | 0.780 | ||
| I | 2 (50.0%) | 13 (23.6%) | |
| IIa | 1 (25.0) | 8 (14.5%) | |
| IIb | 0 (0%) | 3 (5.5%) | |
| III | 1 (25.0%) | 19 (34.5%) | |
| IVa | 0 (0%) | 2 (3.6%) | |
| IVb | 0 (0%) | 10 (18.2%) | |
| Size | 0.248 | ||
| <5 cm | 0 (0%) | 14 (25.5%) | |
| ≥5 cm | 4 (100%) | 41 (74.5%) | |
| Capsule formation | 0.447 | ||
| Present | 0 (0%) | 7 (12.7%) | |
| Absent | 4 (100%) | 48 (87.3%) | |
| Capsule invasion | 0.124 | ||
| Present | 1 (25.0%) | 37 (67.3%) | |
| Absent | 3 (75.0%) | 18 (32.7%) | |
| LN metastasis | 0.576 | ||
| Present | 0 (0%) | 4 (7.3%) | |
| Absent | 4 (100%) | 51 (92.7%) | |
| Distant metastasis | 0.290 | ||
| Present | 0 (0%) | 12 (22.2%) | |
| Absent | 4 (100%) | 42 (77.8%) | |
| Myasthenia gravis | None | ||
| Present | 0 (0%) | 0 (0%) | |
| absent | 4 (100%) | 55 (100%) | |
| Neoadjuvant Tx | 0.546 | ||
| No | 2 (50.0%) | 39 (70.9%) | |
| CTx | 2 (50.0%) | 14 (25.5%) | |
| RTx | 0 (0%) | 2 (3.6%) | |
| Adjuvant Tx | 0.580 | ||
| No | 1 (25.0%) | 16 (29.1%) | |
| CTx | 0 (0%) | 10 (18.2%) | |
| RTx | 3 (75.0%) | 29 (52.7%) | |
| PD-L1 | 0.481 | ||
| High | 2 (50.0%) | 18 (32.7%) | |
| Low | 2 (50.0%) | 37 (67.3%) | |
†
Analyzed using a t-test.
Tx, treatment; CTx, chemotherapy; RTx, radiation therapy.